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Diﬀuse systemic sclerosis (SSc) is a fatal autoimmune disease characterized by an excessive ECM deposition inducing a loss of
function of skin and internal organs. Apoptosis is a key mechanism involved in all the stages of the disease: vascular damage,
immune dysfunction, and ﬁbrosis. The purpose of this paper is to gather new ﬁndings in apoptosis related to SSc, to highlight
relations between apoptosis and ﬁbrosis, and to identify new therapeutic targets.
1.Introduction
Systemic sclerosis (scleroderma, SSc) is a heterogeneous dis-
ease which develops into three forms: limited, intermediate,
and diﬀuse [1]. The limited form only aﬀects skin of the
limbs.Inadditiontocutaneousdisorders,thediﬀuseonealso
aﬀectsinternalorganssuchaslungs,heart,andkidneys.After
adebilitatingphase,themostsevereformleadstodeath.This
disease is characterized by a strong autoimmune reaction,
although it is not clear whether this is a consequence of
the disease or a causal factor. Nevertheless, autoantibodies,
principally raised against nuclear epitopes, are used like
prognostic markers.
In the United States, the disease strikes more African
American people and females than Caucasians and males
[2]. Besides, the disease appears more prematurely in the
African American group and hits them more severely than
the Caucasians [3]. The mortality rate for SSc in the group
of women has increased by seventy percent over the last
twenty years without convincing explanations. The cost of
the medical care associated with this disease was estimated at
more than $20,000 per patient per year in Canada [4]. The
disease is particularly devastating because it strikes people
during the most productive period of their professional life.
The causes of SSc are not clearly identiﬁed. Genetic
factorscouldnotbeexcluded[5,6],butenvironmentalinﬂu-
ence seems to be more important. Notably, chronic exposi-
tion to chemicals, such as organic solvents [7] and silicone
[8], viral infection by cytomegalovirus (CMV), a member
of herpesviruses family [9, 10], and microchimerism [11],
could all play a role in the disease.
It is thought that SSc begins with vasculopathies through
massive endothelial cells death that would lead to oblitera-
t i o no fs m a l la r t e r i e sa n da r t e r i o l e s .I ti sh o w e v e ru n c l e a ri f
autoantibodiesareproducedbeforevasculardamagesand/or
in response to it. Subsequently, cell-to-cell communications
are substantially altered, notably by cytokine and growth
factor secretion dysregulation. The consequence of these
biological changes is an excessive extracellular matrix (ECM)
deposition, ﬁbrosis, in tissues followed by their loss of func-
tion [12]. SSc varies during the progression of the disease,
showing noteworthy changes in ﬁbroblasts phenotype [13].
At the early stage of the disease, cells respond to TGFβ,
but become totally insensitive at the late stage for the most
aﬀected patients, explaining why treatments targeting this
cytokine remain mostly ineﬀective.
Over the last decades, various models had been used
to study SSc [14]. Some animals develop a disease similar2 International Journal of Rheumatology
to this pathology such as UCD-200 chicken, Tsk-1 and -
2 mice. Normal mice could also show some symptoms of
the disease after a treatment with Scl-GvHD, Bleomycin, or
growth factor injection. Nevertheless, several observations
made on these animal models are quite diﬀerent than those
ascertained in humans. Primary cultures of cells isolated
from patients are also widely used, and, more recently, a
new tissue-engineered reconstructed skin model was shown
as a powerful tool to assess the mechanisms involved in the
progression of human SSc [13].
2. A Brief Overview of
theMechanismsof Apoptosis
From the development of the embryo up to its death,
apoptosis plays a crucial role in the induction and the
maintenance of several physiologic functions, at several steps
of both normal and atypic development steps during life. By
eliminating cells during the development of the embryo, it
assists at leading the modeling patterns of the body. It also
contributes to eliminating the nonfunctional neurons and
allows the selection of the adequate synaptic connections.
Later, it allows the elimination of unsuitable lymphocytes
(AICD, activation-induced cell death) [15], preservation of
the homeostasis [16, 17], contributing to the maintenance of
the functional status of the immune system by eliminating
deviant or infected cells. However, an unbalanced ratio
between the various factors involved in apoptotic pathways
can lead to excessive cell proliferation and potentially to
cancer or, on the contrary, to neurodegenerative diseases
(Alzheimer, Parkinson), autoimmune diseases (rheumatoid
arthritis), or immunosuppressive diseases (AIDS).
Apoptosis,orprogrammedcelldeath,shouldnotbecon-
fused with necrosis. The apoptotic process occurs according
to speciﬁc and sequential steps that have been documented.
In contrast, necrosis results from passive mechanisms that
lead generally to an inﬂammatory process while apoptosis
does not [18]. Apoptotic cells are truly destroyed from the
inside and quickly removed from the tissues, a situation that
seriously delayed the discovery of this physiologic process
[19].Apoptosisisregulatedthroughasequenceofeventsthat
have been described. First, the cellular morphology changes
withtheformationofstructuresinbubbles,roundingofcells
probably related to a disorganization of actin ﬁlaments, a
reduction of the cytoplasmic volume, a weakening of mito-
chondrial membrane, facilitating the liberation of various
factors. The chromatin condenses, and the DNA is cleaved
at the level of nucleosomes, before the fragmentation of the
cell nucleus. Finally, the cells are fragmented into apoptotic
bodies that are mainly cleared by macrophages.
Several mechanisms are described as playing a role in
the induction of apoptosis [20]. Following a proapoptotic
stimulus, a cascade of speciﬁc proteases is activated in the
cell. These proteases are called caspases, cysteinyl aspartic
acid proteases [21]. Caspases are produced as proenzymes
w h i c hm u s tb ec l e a v e dt ob e c o m ea c t i v e .P r o t e a s es p e c i ﬁ t y
is deﬁned for each caspase by an aspartic acid containing
consensual sequence in target proteins. Caspases involved
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Figure 1: Major apoptotic pathways. Schematic representation of
intrinsic, mitochondrial, and extrinsic, death receptor, pathways.
Proapoptotic molecules are inbold and antiapoptotic are in italic.
in apoptosis could be classiﬁed in 2 groups: the initiator or
apical caspases, like caspase-8 and caspase-9, whose role is to
activate the other caspases, and the eﬀector or downstream
caspases, like caspase-3, which generally cleave vital targets.
Apoptotic pathways diﬀer according to the nature of the
inductor and the cell type, making their study very complex,
especially in vivo. Nevertheless, two main pathways can be
distinguished: the mitochondrial, or intrinsic, pathway and
the cell death receptors, or extrinsic, pathway (Figure 1).
There are numerous connections between these two path-
ways, then it could be diﬃcult to separate them. Other
pathways have also been described, but would be of lesser
importance.
The mitochondrial pathway seems to be the most
common apoptotic mechanism, and it is well documented
[22]. Under the inﬂuence of several stimuli (ultraviolet irra-
diations, chemical damage, etc.), proteins of the Bcl family
act independently or in complexes on the mitochondrial
membrane [23, 24]. Bcl family proteins could be separated
in proapoptotic proteins (Bax, Bak, Bok, Bcl-Xs), which
destabilize the mitochondrial membrane, antiapoptotic pro-
teins (Bcl-2, Bcl-XL, Bcl-W, Mcl-1, Bcl-2A1), that protect
this membrane and proapoptotic BH3-only proteins (Bad,
Bid, Bik, Bim, Puma, Noxa), which inhibit the antiapoptotic
function of the Bcl-2-like proteins [25]. Under Bcl proapop-
totic protein inﬂuence, mitochondrial pores open and lead
to depolarization of the membrane releasing proapoptotic
factors such as cytochrome C. The latter associates with
the adaptor Apaf-1 (apoptosis-associated factor-1) and
procaspase-9. In presence of dATP, this complex, named
apoptosome, leads cleavage and activation of procaspase-
9 which responds by cleaving procaspase-3 to activate it.
Caspase-3 degrades its substrates such as ICAD/DFF45,
an inhibitor of the endonuclease CAD/DFF40 (caspase
associated DNAse), responsible for the fragmentation of the
DNA. Various inhibitors exist for this pathway such as some
antiapoptotic proteins of the Bcl family [23], preventing
the depolarization of the mitochondrial membrane. Further-
more, when phosphorylated by AKT/PKB, Bad, a proapop-
totic member of this family could be sequestrated by theInternational Journal of Rheumatology 3
protein 14.3.3 [26]. This action prevents Bad to bind to Bcl-
xL and inactivate its protective function. IAP (inhibitor of
apoptosis protein) could also block mitochondrial apoptosis
by inhibiting the cleavage of procaspases 3, 7, and 9 [27, 28].
Other pathways that are dependent from mitochondria but
independent from caspases can also be activated, notably
by the factor AIF (apoptosis inducing factor) released from
mitochondria [29].
The second best known apoptotic pathway, the cell
death receptor (DR) pathway, has also been extensively
studied [30–32]. Until now, about ﬁfteen DRs from the
TNF (tumor necrosis factor) receptor family were identiﬁed.
Some are well known, especially TNFR-1/p55 and Fas/Apo-
1/CD95. They are characterized by an extracellular domain
consisting of cysteyl-rich regions (from 1 to 6 repeats),
a transmembrane domain, and an intracellular domain
carrying a deathdomain region (DD).Insertedin the plasma
membrane of the cells, monomeric or trimeric forms of
receptors are clustered into microdomains called lipid rafts
[33–35].TheDRligandsaremostlytransmembraneproteins
that must be matured by proteolytic cleavage [36]. Once
released, they could bind their receptors although it has
been shown that Fas ligand (FasL) and the membrane form
of the TNF (mTNF which is especially bound to TNFR-
2[ 37]) can also act in a transmembrane form. Activation
of TNFR and Fas [38] induces a wide range of functions
such as cellular proliferation, cell survival and apoptotic
cell death, cell diﬀerentiation, inﬂammation, and defense
againstmicroorganisms(viral,bacterial,fungal,andparasitic
infections) [39]. Output of ligand binding is determined by
cellular environment and adapter molecules availability.
According to the cells, mechanisms to induce apoptosis
via DR pathway are diﬀerent. In type-I cells, proapoptotic
cascade is fast and unaﬀected by a Bcl-2 overexpression,
while, in type-II cells, apoptotic cascade is slower, demon-
strates an activation of procaspase-9, and is sensitive to Bcl-
2 antiapoptotic activity [40]. In type-I cells, such as dermal
ﬁbroblasts, Fas activation by FasL leads to the recruitment
of FADD (Fas-Associated DD), an adapter protein [41].
FADD shares homologous domains with its partners: DD
with receptor and Death Eﬀector Domain (DED) with apical
caspases. FADD allows the recruitment and self-activation
of procaspase-8, which can consequently cleave and activate
procaspase-3. This pathway is tightly modulated by c-FLIP
(cellular-ﬂiceinhibitoryprotein)[42,43],acaspasehomolog
without any proteolytic activity. cFLIP can bind FADD or
procaspase-8 and prevents its activation. Once more, IAP
could inhibit caspase-3 activity.
Mechanisms associated to apoptosis of type-II cells seem,
at least partially, common with the mitochondrial pathway.
In these cells, caspase-8 activity is weak, and one of its
targets is Bid, of which the truncated form, t-Bid, acts on
mitochondria [44].
Mitochondrial and DR pathways could be regulated by
the activation of the MAPK (Mitogen-Activated Protein
Kinase) cascade [45]: p38 MAPK, ERK (Extracellular signal-
Regulated Kinase) and JNK (Jun N-terminal Kinase) or by
those of NFκB( N u c l e a rF a c t o r - κB) [46]. MAPK activation
could lead to survival or apoptosis, depending on the
strength and duration of the signal. The antiapoptotic
function of these kinases mostly results from transcription
factor activation, leading to antiapoptotic proteins synthesis,
notably from the Bcl family. NFκB exists on an inactive form
linked to inhibitor IκB. Phosphorylation and subsequent
degradation of this protein release a phosphorylated form
of NFκB which translocates to the nucleus and activates not
only the expression of c-FLIP [47], but also the expression
of c-IAP1 and 2, XIAP, and other various antiapoptotic
proteins.
Although less studied, other apoptotic pathways are
documented. Cytolytic granules are specialized secretory
lysosomes mainly composed of perforin and granzymes.
Granules are secreted by killer cells, such as natural killer
(NK) or cytotoxic T lymphocytes (CTLs) to control viral
infection, intracellular pathogen dissemination, and tumori-
genesis. After granule is released in immunological synapses,
perforin opens cell membrane allowing entry of granzyme
into the cell using a still unclear mechanism. Granzyme
B cleaves and activates not only procaspase-3 but also
Bid in its t-Bid form and ICAD to release DNAse CAD.
Granzymes A and C do not activate procaspases but act on
mitochondrial membrane to induce apoptosis. Granzyme
A could also target SET complex in endoplasmic reticulum
which in turn induces DNA damage [48, 49]. Endoplasmic
reticulum (ER) cell responses are important to appropriately
answer to unfolded proteins but, when unresolved, they
could induce apoptosis [50, 51]. ER stress induces apoptosis
through mitochondria or activation of procaspase-12 and
subsequently procaspase-3 [52].
Our aim was not to give an exhaustive description of
apoptosis, and we voluntary restrain it to major pathways.
Very interesting reviews could be read on other forms of cell
death, especially necrosis, oncosis [53], and necroptosis, a
well-organized death [54].
3.FibrosisandApoptosis
Links between apoptosis and ﬁbrosis emerged with force
during the late 1990s. The level of the soluble form of
Fas, sFas (a receptor antagonist for the proapoptotic protein
Fas [55]), in sera from aﬀected patients is higher than the
one of normal volunteers in idiopathic pulmonary ﬁbrosis
[56] and silicosis [57]. This increased sFas serum level
could play a role in preserving a subset of dysfunctional
lymphocytes. Activated but unwanted lymphocytes which
are normally eliminated by Fas activation could remain and
induce ﬁbrosis. They could also increase the ﬁbroblastic
cellularity and consequently the collagen deposition. The
Fas/FasL system in T cells is also altered after silica exposure
and leads to silicosis [58]. Whereas pulmonary ﬁbrosis
involves an increased resistance to apoptosis [59, 60], Fas
is downregulated in ﬁbrotic ﬁbroblast membrane [56]a n d
the proapoptotic Bid was shown to be required to induce
ﬁbrosis [61]. As in silicosis, the Fas/FasL system was thus
thought to play a key role in several other pulmonary ﬁbrotic
pathologies [62, 63].
Similar results were observed in SSc. For instance, an
i n c r e a s e dl e v e lo fs F a si nS S cs e r u m[ 64, 65]a n dah i g h e r4 International Journal of Rheumatology
resistance of pathological ﬁbroblasts to Fas apoptosis [66–
69]havebeenreported.Somestudieswithbleomycin-treated
mice indicated that the Fas/FasL pathway is critical for the
development of SSc pathology. Animals devoid of Fas or
FasL genes [70] or treated with anti-FasL antibodies [71]
show a decrease of apoptosis and a concomitant decrease
of collagen accumulation. SSc aﬀects the immune system
of the patients since changes in Th1/Th2 response were
detected resulting in an inadequate proﬁbrotic activation
[72–77]. Several authors attribute the antiﬁbrotic eﬀect
of the Fas pathway deletion to a decreased selection of
alteredproﬁbroticlymphocytessubset.Theselectionofthese
abnormal lymphocytes would mainly result from a deﬁcient
apoptoticprocess[78,79].ItcouldalsobenotedthatThcells
have diﬀerent sensitivity from Fas-induced apoptosis and
that diﬀerence could be explained by cFLIP expression level.
Th2 and Th17 are naturally more resistant to Fas-induced
cell death than Th1 [80]. Fas activation could then lead to
selection of a Th2/Th17 response to the detriment of Th1.
This is the immunologic pattern generally expected in SSc.
Overexpression of FLIP decreases sensitivity of all these cells
[81] and could reverse autoimmune disease in animal model
[82]. sFas levels could then be an attempt to patient to stop
the Th1 to Th2/Th17 ﬁbrotic switch.
SSc also aﬀects the vascular network and a lot of
evidences pointed out apoptosis as an eﬀector. Sera from
patients have been shown to induce apoptosis according
to several mechanisms. Antiendothelial cells antibodies
(AECAs), a heterogeneous group of antibodies directed
againstproteinsandmoleculesspeciﬁcallypresentonsurface
and inside of endothelial cells, induce apoptosis by stimu-
lating Fas [83] or activating procaspase-3 [84]. Apoptosis
could also be ampliﬁed when a patient is infected by CMV,
one of the putative cause of SSc. This ampliﬁcation was
done via viral UL94 protein [85]. In SSc patients, sera could
also induce endothelial apoptosis via secretion of IL-6 by
monocytes (or ﬁbroblasts) and E selectin expression [86].
In healthy people, a break in the vascular network results
in a quick repair and the reconstitution of small vessels
via angiogenesis. In SSc patients, this repair is blocked by
the death of both, endothelial progenitor cells (EPCs) and
circulating angiogenic cells (CACs). Death of EPC results
f r o mf a c t o r st h a ta r ep r e s e n ti nS S cp a t i e n ts e r as u c ha s
AECA [87]. In EPC exposed to SSc patient sera, pAKT
is reduced and could not inhibit the phosphorylation of
FOXO3a and Bim, a proapoptotic Bcl-2 family member,
is increased [88]. Furthermore, authors have demonstrated
that CAC are killed by microparticules (MPs) released by
apoptotic endothelial cells. These MP membranes are rich
in arachidonic acid, which induces mitochondrial death of
CAC [89, 90]. Tweak, known for its capacity to preserve
and develop vascular network, is decreased in SSc patient
sera with pulmonary aﬀection [91], but not in sera of
SSc patients with unaﬀected lungs [92]. This impairment
of vascular endothelial repair results in hypoxia, which, in
turn, could induce apoptosis in immune system cells and
ﬁbroblasts. Together with proﬁbrotic IL4 cytokine, widely
expressed in SSc, hypoxia also results in an increase in
Lysyl-hydroxylase-2 and an alteration of the type-I collagen
crosslinking [93]. Hypoxia also helps to stimulate ECM
deposition, and, in a vicious loop, such tissue ﬁbrosis
induces more hypoxia [94]. Apoptosis of endothelial cells
has other eﬀects, notably on ﬁbroblasts, discussed in the next
paragraphs.
Some evidence indicates apoptotic epithelial cells could
play a role in ﬁbrosis, especially in lung of bleomycin-treated
mice [95, 96]a sw e l la si nan e wS S cm o u s em o d e l[ 97]
and human Idiopathic Pulmonary Fibrosis [98]. Epithelial
cell death is clearly mediated through Fas/FasL pathway.
Activated T cell and ﬁbrotic ﬁbroblasts could express FasL
and induce apoptosis in lung epithelium [99]. During
repetitive cycles of epithelial injury, epithelial cells release
cytokines and growth factors, which promote ﬁbroblast
activation such as in wound healing process. These chronic
phenomena lead to ﬁbrosis.
Recent data indicate that SSc patient epidermis is
abnormal and play a role due to its interaction with dermis
[100, 101] like it was shown previously in skin wound
healing [102]. SSc keratinocytes promote release of TGFβ,
a ﬁbrosing agent, from ﬁbroblasts and secrete themselves
CTGF, which stabilize the ﬁbrotic phenotype of ﬁbroblasts.
Change in epidermis-dermis interaction in SSc is thought to
result from chronic epidermis injury. The exact cause of this
injury remains unclear but a limited apoptosis could not be
excluded at this level, especially due to results obtained in
lung ﬁbrosis.
Fibroblasts, the major ECM secreting cells, also play a
role in the evolution of SSc. Many studies focus on the
regulation of ﬁbroblast apoptosis in relation with ﬁbrosis. It
is thought that proﬁbrotic cells are more resistant to apop-
tosis than others, maintaining their presence in situ despite
immune system endeavour to remove them. This has been
observed in various types of ﬁbrosis such as hypertrophic
scars [103, 104], pulmonary ﬁbrosis [59, 60], and SSc [66–
69]. Proteins from the mitochondrial pathway seem to be
involved in the apoptotic resistance as well as death receptors
proteins and several elements connecting both pathways.
Some studies highlight proteins of mitochondrial pathway.
Bax expression is decreased in SSc dermal ﬁbroblasts [69]
but Bcl-2 could be increased [105]. pAKT is increased in SSc
ﬁbroblasts [105, 106] and then could inhibit Bad proapop-
totic function. The Fas pathway is also repressed in SSc with
c-FLIPs and through c-IAP overexpression [67]. In other
studies, protective potential of SSc ﬁbroblast is explained
by modulation of transcription of antiapoptotic proteins
through kinase cascade. MAPK pathway, including ERK, is
also activated by pFAK [107, 108]: the result of such activa-
tion could lead to the expression of antiapoptotic proteins.
MIF [105], an ERK activator inducing Bcl-2 expression, and
AKT, or PKCε [66], responsible for MAPK activation, are
both reported to be involved in the modulation of apoptosis
in SSc ﬁbroblasts. Involvement of ROS in SSc is known
for a long time [109]; they result mainly from vascular
damage and inﬂammatory process. Besides protein and lipid
oxidation, they induce DNA damage in ﬁbroblasts [110]b u t
seem to play little or no role in SSc-related vasculopathy. It is
howeverwellknownthatDNAdamagecould,inturn,induce
apoptosis.International Journal of Rheumatology 5
4. Selection of Proﬁbrotic Fibroblast
Populations: Role of Apoptosis
Several groups have postulated that lesional SSc ﬁbroblasts
could have been selected through unknown mechanisms
from a subpopulation already present in situ, prior to the
emergence of the ﬁrst lesions.
Fibroblasts are heterogeneous in terms of their collagen
secretionpattern[111]thattheyretainforseveralpassagesin
vitro [112]. In SSc lesions, there is an increase in ﬁbroblasts
producing high levels of collagen and this phenotype is
also retained in vitro [111–113]. A clonal selection of
high-collagen-producing ﬁbroblasts had been proposed as a
mechanism for scleroderma-associated ﬁbrosis onset [114].
It is postulated that the increase of the high collagen
producing cells in SSc tissues could result either from a
higher proliferative capacity or from a higher resistance to
apoptosis of these cells. Some authors have shown that an
exposure of ﬁbroblasts to SSc sera increases the proportion
of ﬁbrotic ﬁbroblasts [112], but others do not [115]. Lesional
SSc ﬁbroblasts do not grow at higher proliferation rates than
normal ones in monolayers [67] or in three-dimensional
tissue engineered cultures [13]. Recent evidences point out
apoptosis resistance as the main mechanism from which
proﬁbrotic/apoptosis-resistantcellsubpopulationsemergeat
the detriment of healthy cells leading to the development
of ﬁbrotic lesions. Fibroblasts from nonlesional area of late
stage SSc patients exposed to FasL show an increased resis-
tance to Fas-induced apoptosis and a decrease of their MMP
secretion, which could result in higher ECM deposition. A
similar mechanism was described for metastatic cancer cells
[116].
5. AreApoptosis Resistance andProﬁbrotic
Potentialof FibroblastsRelated to
or Resulting from Independent but
Concomitant Mechanisms?
During SSc development, ﬁbroblasts are surrounded by
numerous proapoptotic and proﬁbrotic stimuli [76, 115,
117]. It could be interesting to relate both events. After
vascular damage, thrombin is released in order to form a
ﬁbrin clot, but it also activates PAR-1, inducing the modu-
lation of the ﬁbroblast phenotype from quiescent to ﬁbrotic.
At the same time, thrombin promotes ﬁbroblast apoptosis
resistance through the eﬀect of p21Cip1/WAF1. This protein
induces PKCε activation that inhibits Fas/FasL signaling
and reduces or slows down apoptosis [66]. Endothelial
cell death leads to the local diﬀusion of several mediators
including not only CTGF [118], a protein involved in the
stimulation of ﬁbrosis [119], but also some antiapoptotic
factors that may promote the maintenance of lesional
SSc ﬁbroblasts on site [120]. Various types of cells died
through apoptosis during SSc, probably due to patient sera
composition, FasL exposition, or hypoxia. Apoptotic bodies
released from such dead cells may contribute to the survival
ofﬁbroblaststhatexhibitaproﬁbroticphenotypeinresponse
to macrophages TGFβ secretion [121]. It is interesting to
note that Thrombospondin-1 (TSP-1) is increased in SSc
and activates the release of TGFβ from latent complex
[122]. TSP-1, released from apoptotic ﬁbroblasts, is also
responsible of the activation of apoptotic body phagocytosis
by macrophages [123].SomemicroRNAsrecentlydiscovered
also seem to play a role in the potential interactions between
apoptosis and ﬁbrosis. Mir-29b decreases the expression
of Mcl-1, a Bcl-2 family member [124], sensitizing cells
to apoptosis. Mir-29a has been demonstrated to repress
collagen synthesis, and it is signiﬁcantly poorly detected
in SSc ﬁbroblasts [125]. Finally, Mir-29a/b transcription is
modulated by NFκB[ 126], a protein with dual roles in
apoptosis.
Nevertheless, the protein that seems to be the most
relevant to link apoptosis and ﬁbrosis is IL-6. IL-6 is strongly
overexpressed in SSc [76, 86, 117, 127–131]. This cytokine
is known to induce a relocalization of receptors outside
lipid rafts (Figure 2). This change of compartmentalization
increases TGFβ signaling and collagen synthesis [132].
Interestingly, in response to IL-6, ﬁbrotic cells become more
resistant, and normal ﬁbroblasts become more sensitive to
apoptosis [133]. It is not known if IL-6 can change Fas
localization outside lipid rafts in ﬁbrotic cells and inside
the rafts in normal cells. However, several authors have
demonstratedthattranslocationofFasinlipidraftsincreases
cellular response to apoptosis [134–139].
6. New TherapeuticTargets
No treatment is currently available to help SSc patients who
deal with a major loss of function and a poor quality of life.
A deeper knowledge of the mechanisms underlying SSc is
thus required to identify new therapeutic targets to establish
a therapeutic strategy to control or cure SSc [140]. As the
primary causes of the disease are unknown, it is necessary
to target the secondary causes. Apoptosis is the heart of the
SSc. In every stage, establishment and maintenance of the
disease,thisphenomenonplaysacrucialrole.So,itshouldbe
possible to modulate apoptosis to block the development of
the disease and, perhaps, to go back towards a healthy status
especially for early stage of the disease.
6.1. Targeting Immune System Cells Apoptosis. In SSc, Th
balance is in favor of Th2–Th17 cells allowing secretion
of proﬁbrotic cytokines as TGFβ and IL6 rather than Th1
cells, TNFα secreting cells, which are less harmful. Sensitivity
of Th cells to Fas-induced apoptosis favors clonal selection
of Th2–Th17 cells, which express more cFLIP than Th1
cells. Overexpression of cFLIP in a transgenic mouse model
leads to restoration of Th balance [82]. Nevertheless, cFLIP
accumulation should be restrained to lymphocytes because
cFLIP presence also promotes ﬁbroblast resistance to Fas-
induced apoptosis and selection of ﬁbrotic dermis cells [67].
Gene therapy could achieve this goal but no safe and eﬃcient
gene transfer protocol is available for now.
It had been observed that SSc patient peripheral blood
mononuclear and T cells secrete more sFas, the soluble form
of Fas, to trap FasL, and thus to reduce apoptosis in tissue.
It is believed that this strong sFas secretion could result in6 International Journal of Rheumatology
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Figure 2:HypotheticmechanismofFasL/IL6selectionofpreﬁbroticﬁbroblastinsclerodermalesions.Aftervasculardamage,variousfactors
aredirectlysecretedbyapoptoticendothelialcellsoraresecretedbymacrophages,Tcells,andﬁbroblastsinresponsetoendothelialcelldeaths
andsubsequenthypoxia.MoreproximalcellsbecomepreﬁbroticbyincreasingtheirresponsetoTGFβ.IL-6secretioninducesamoreﬁbrotic
phenotype for cells and increases apoptosis-resistant feature of proﬁbrotic ones. FasL secreted by inﬁltrating cells kills nonﬁbrotic ﬁbroblast
with low or none eﬀect on ﬁbrotic cells. ECM is then deposited in excess and organ fails.International Journal of Rheumatology 7
a selection of an unwanted subset of proﬁbrotic-activated
lymphocytes, but in the light of the results mentioned below,
italsocouldbeanunsuccessfulattempttorestoreThbalance.
In this case, treatment with recombinant sFas could favor
Th1 cells. Injection of blocking but not activating anti-Fas
antibodies or anti-FasL could also be envisaged [71]. In the
same vein, downregulation of Fas exposition at the surface of
the cells [141] or a decrease of the Fas concentration in lipid
rafts could also be tested [138, 142]. As it has been shown
in transgenic mouse model where Fas or FasL genes were
deleted, Fas/FasL pathway abolition could thus result in an
abrogation of ﬁbrosis development [70].
Finally,severalstudieslinkbreastcancerandscleroderma
[143]. Tamoxifen was known to restore Th1/Th2 balance
[144] and could be a candidate to potentially block the
disease evolution.
6.2. Targeting Endothelial Cells Apoptosis. Vasculopathy is an
early event in the development of SSc, and a lot of patients
receivedtheir SSc diagnostic whenthey consultforRaynaud-
like symptoms. Then, endothelial cell apoptosis managing
couldbeavaluablestrategy.Atthislevel,protectingendothe-
lialcellsortheirprecursorsisaneed.Aspreviouslydescribed,
SSc pathologic process targets not only endothelial cells from
microvessels but also the mechanism to repair the vascular
damage.
Endothelial cell apoptosis is induced by pathologic
serum exposition especially AECA. Two strategies could be
developed: to determine what are the antigens recognized by
these antibodies and to inject recombinant peptides to block
their action or to design antibodies raised against AECA to
inactivate them. The initial vasculopathy blocking should
then stop the disease at a very early stage.
I no r d e rt oa l l o wa ne ﬃcient repair of microvessel,
restoration of microcirculation, and reversion of ﬁbrosis, it
is also required to prevent EPC and CAC death. Arachidonic
acid containing MP could be counteracted by Oltipraz and
1,2-dithiole-3-thione congeners [145]. VEGF and/or PDGF
treatment could also been envisaged to maintain or restore
microvasculature. This therapy should however be coupled
with another one that can block endothelial cell apoptosis.
6.3. Targeting Epithelial Cells Apoptosis. Apoptosis modula-
tion in the lung epithelial compartment could be achieved
by reducing exposition of FasL to the surface membrane
of activated ﬁbroblasts or to decrease Fas at the surface
of the lung epithelium. Epithelia are very accessible tissue
to therapy due to their localization in direct contact with
outside. Gene therapy assay to reduce Fas expression should
thus be easily driven.
6.4. Targeting Fibroblasts Apoptosis. Because ﬁbroblasts se-
crete ECM responsible of ﬁbrosis, these cells should be
targeted as soon as ﬁrst ﬁbrotic symptoms are obvious. The
challenge of this step is the very heterogeneous molecular
results at the origin of ﬁbroblast resistance to apoptosis. The
diversity of the mechanisms, and then of the antiapoptotic
proteins involved, could result from the various disease
aetiologies, the ethnic patient origins, or the model used.
Nevertheless, a precise deﬁnition of the apoptotic mecha-
nism involved for each patient is clearly needed.
Hyaluronan could be a valuable molecule to treat
this pathology. Hyaluronan decreases collagen synthesis by
reverting localization of TGFβ receptors in nonsignaling
membranedomain [146].ItalsoinducestranslocationofFas
into lipid rafts and then sensitizes cells to apoptosis [136].
Similar eﬀects on Fas recruitment in lipid rafts are obtained
with edelfosine, an inhibitor of PI3K [33, 134, 135, 137].
In the same way, restoring expression of Caveolin-1
could be of a great help. Cav-1 expression is reduced in
SSc [147], as well as in some breast cancers [148], and
this decrease favors localization of TGFβ receptors outside
lipid rafts and towards signalling domains. Besides, Fas is
eﬀective to induce apoptosis when presents in lipid rafts. So
Cav-1 underexpression could explain, at least partially, the
resistance of ﬁbrotic ﬁbroblasts to Fas-induced apoptosis.
Restoration of Cav-1 expression level could thus help to
reverse ﬁbrosis.
Curcumin could also provide a promising strategy for
the treatment of SSc. Curcumin has been shown to induce
apoptosis in ﬁbrotic cells only [149]. This molecule is
widely used in traditional south-east Asian cooking and
f o rc a n c e rt r e a t m e n t[ 150–154]. It is a safe drug but its
optimaleﬀectisobtainedwhenadministeredincombination
with other drugs. Another natural product, Resveratrol, has
proapoptotic properties which could be used to sensitize
ﬁbrotic cells to apoptosis [155, 156]. This molecule inhibits
Mcl-1 and Bcl-XL which are both known to play a role
in apoptotic resistance of ﬁbroblasts in SSc. Resveratrol
also counteracts AKT and MAPK pathways. Regulation of
oxidativestresshasbeenextensivelypreviouslydescribedand
may help to deﬁne antioxidant therapy to restore normal
function of organs including skin [157].
In order to increase Fas sensitivity of ﬁbrotic cells,
thalidomide could be used. Thalidomide has been shown
to increase Fas number [158]. Presence of inﬁltrating T
cells producing FasL in SSc tissues could thus result in the
elimination of ﬁbrotic cells. Thalidomide is currently used
for the treatment of autoimmune diseases [159] inducing
apoptosis through an unknown mitochondrial pathway
[160]. Restored levels of mir-29a/b could also be of a great
help to control scleroderma but further studies based on
microRNA seem to be necessary. Sexual hormones such
as oestradiol and testosterone could also modulate the
expressionandthesensitivityofcellstotheFasL/Faspathway
[161]. As the majority of SSc patients are women who
have reached the end of their active reproductive period,
the potential adverse eﬀects of hormonal treatment could
be minimized, with a rigorous clinical monitoring. Control
of cFLIP and cIAP expression using siRNA or antisense
oligonucleotide could also be of interest [67]. Anticancer
therapytargetstheseproteins[162].Inthecaseofﬁbroblasts,
cFLIPexpressionlevelneedtobedecreasedinﬁbroticcellsor
increased in their nonlesional counterparts. cIAP is a more
complex protein to modulate due to its redundant isoforms
but could not be eluded due to its numerous biological
functions and its potential role in SSc.8 International Journal of Rheumatology
7. Concluding Remarks
Apoptosis plays a key role in emergence and maintenance of
SSc. Apoptosis is involved in immune system response by
changing the subset of inﬁltrating cells, in vascular damage
and its consequences, and ﬁnally in selecting ﬁbroblasts with
proﬁbrotic phenotype, responsible of loss of function of
organs and fatal outcome. Depending on the patient, molec-
ular mechanisms could be diﬀerent and involve diﬀerent
proteins. Nevertheless FasL/Fas seems to play a key role.
A deeper knowledge of how apoptosis modulates ﬁbrosis
could allow the development of new therapies adapted to the
apoptotic proﬁle of patients and, thus, to cure the disease
with the least adverse side eﬀects.
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